AAAAAA

   
Results: 1-25 | 26-29
Results: 1-25/29
Growth phase-associated changes in protein expression in Mycobacterium smegmatis identify a new low molecular weight heat shock protein
Authors: Ntolosi, BA Betts, J Zappe, H Powles, R Steyn, LM
Citation: Ba. Ntolosi et al., Growth phase-associated changes in protein expression in Mycobacterium smegmatis identify a new low molecular weight heat shock protein, TUBERCULOSI, 81(4), 2001, pp. 279-289
The implication of compromised renal function at presentation in myeloma -Similar outcome in Patients who receive high-dose therapy: A single-centerstudy of 251 previously untreated patients
Authors: Sirohi, B Powles, R Mehta, J Treleaven, J Raje, N Kulkarni, S Rudin, C Bhagwati, N Horton, C Saso, R Singhal, S Parikh, P
Citation: B. Sirohi et al., The implication of compromised renal function at presentation in myeloma -Similar outcome in Patients who receive high-dose therapy: A single-centerstudy of 251 previously untreated patients, MED ONCOL, 18(1), 2001, pp. 39-50
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia
Authors: Visani, G Milligan, D Leoni, F Chang, J Kelsey, S Marcus, R Powles, R Schey, S Covelli, A Isidori, A Litchman, M Piccaluga, PP Mayer, H Malagola, M Pfister, C
Citation: G. Visani et al., Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia, LEUKEMIA, 15(5), 2001, pp. 764-771
Comparison of new patients with Bence-Jones, IgG and IgA myeloma receivingsequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria
Authors: Sirohi, B Powles, R Kulkarni, S Rudin, C Saso, R Lal, R Singhal, S Mehta, J Horton, C Treleaven, J
Citation: B. Sirohi et al., Comparison of new patients with Bence-Jones, IgG and IgA myeloma receivingsequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria, BONE MAR TR, 28(1), 2001, pp. 29-37
Use of first line bronchoalveolar lavage in the immunosuppressed oncology patient
Authors: Murray, PV O'Brien, MER Padhani, AR Powles, R Cunningham, D Jeanes, A Ashley, S
Citation: Pv. Murray et al., Use of first line bronchoalveolar lavage in the immunosuppressed oncology patient, BONE MAR TR, 27(9), 2001, pp. 967-971
Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey
Authors: Salooja, N Szydlo, RM Socie, G Rio, B Chatterjee, R Ljungman, P Van Lint, MT Powles, R Jackson, G Hinterberger-Fischer, M Kolb, HJ Apperley, JF
Citation: N. Salooja et al., Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey, LANCET, 358(9278), 2001, pp. 271-276
Some early phase II trials in previously untreated multiple myeloma: The Royal Marsden experience
Authors: Sirohi, B Kulkarni, S Powles, R
Citation: B. Sirohi et al., Some early phase II trials in previously untreated multiple myeloma: The Royal Marsden experience, SEM HEMATOL, 38(3), 2001, pp. 209-218
Hematopoietic reconstitution by transplantation of stem cells from bone marrow or blood.
Authors: Singhal, S Powles, R Mehta, J
Citation: S. Singhal et al., Hematopoietic reconstitution by transplantation of stem cells from bone marrow or blood., N ENG J MED, 344(21), 2001, pp. 1641-1641
Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres
Authors: Gahrton, G Svensson, H Cavo, M Apperley, J Bacigalupo, A Bjorkstrand, B Blade, J Cornelissen, J de Laurenzi, A Facon, T Ljungman, P Michallet, M Niederwieser, D Powles, R Reiffers, J Russell, NH Samson, D Schaefer, UW Schattenberg, A Tura, S Verdonck, LF Vernant, JP Willemze, R Volin, L
Citation: G. Gahrton et al., Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres, BR J HAEM, 113(1), 2001, pp. 209-216
Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma
Authors: Sirohi, B Powles, R Kulkarni, S Rudin, C Saso, R Rigg, A Horton, C Singhal, S Mehta, J Treleaven, J
Citation: B. Sirohi et al., Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma, BR J CANC, 85(3), 2001, pp. 325-332
Paradoxical emboli after central venous catheter removal
Authors: Zuha, R Price, T Powles, R Treleaven, J
Citation: R. Zuha et al., Paradoxical emboli after central venous catheter removal, ANN ONCOL, 11(7), 2000, pp. 885-886
Interleukin-6 and other gp130-dependent cytokines selectively inhibit proliferation of macrophage-lineage hemopoietic progenitor cells
Authors: Clutterbuck, R Powles, R Millar, J Catovsky, D
Citation: R. Clutterbuck et al., Interleukin-6 and other gp130-dependent cytokines selectively inhibit proliferation of macrophage-lineage hemopoietic progenitor cells, EXP HEMATOL, 28(10), 2000, pp. 1120-1128
A low CD34(+) cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34(+) cells/kg be considered the minimum threshold?
Authors: Singhal, S Powles, R Treleaven, J Kulkarni, S Sirohi, B Horton, C Millar, B Shepherd, V Tait, D Saso, R Rowland, A Long, S Mehta, J
Citation: S. Singhal et al., A low CD34(+) cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34(+) cells/kg be considered the minimum threshold?, BONE MAR TR, 26(5), 2000, pp. 489-496
Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients
Authors: Powles, R Sirohi, B Kulkarni, S Bhagwati, N Saso, R Raje, N Horton, C Singhal, S Mehta, J Treleaven, J
Citation: R. Powles et al., Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients, BONE MAR TR, 25(9), 2000, pp. 949-956
Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission - long-term follow-up
Authors: Vaidya, SJ Atra, A Bahl, S Pinkerton, CR Calvagna, V Horton, C Milan, S Shepherd, V Brain, C Treleaven, J Powles, R Tait, D Meller, ST
Citation: Sj. Vaidya et al., Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission - long-term follow-up, BONE MAR TR, 25(6), 2000, pp. 599-603
Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation
Authors: Singhal, S Powles, R Kulkarni, S Treleaven, J Sirohi, B Millar, B Shepherd, V Saso, R Rowland, A Long, S Cabral, S Horton, C Mehta, J
Citation: S. Singhal et al., Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation, BONE MAR TR, 25(5), 2000, pp. 501-505
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over
Authors: Sirohi, B Powles, R Treleaven, J Mainwaring, P Kulkarni, S Pandha, H Bhagwati, N Horton, C Singhal, S Mehta, J
Citation: B. Sirohi et al., The role of autologous transplantation in patients with multiple myeloma aged 65 years and over, BONE MAR TR, 25(5), 2000, pp. 533-539
Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years
Authors: Kulkarni, S Powles, R Treleaven, J Singhal, S Horton, C Sirohi, B Bhagawati, N Tait, D Saso, R Killick, S Pinkerton, R Atra, A Meller, S Mehta, J
Citation: S. Kulkarni et al., Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years, BONE MAR TR, 25(4), 2000, pp. 365-370
Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia
Authors: Frassoni, F Labopin, M Powles, R Mary, JY Arcese, W Bacigalupo, A Bunjes, D Gluckman, E Ruutu, T Schaefer, UW Sierra, J Vernant, JP Willemze, R de Witte, T Gorin, NC
Citation: F. Frassoni et al., Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia, LANCET, 355(9213), 2000, pp. 1393-1398
Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial
Authors: Powles, R Mehta, J Kulkarni, S Treleaven, J Millar, B Marsden, J Shepherd, V Rowland, A Sirohi, B Tait, D Horton, C Long, S Singhal, S
Citation: R. Powles et al., Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial, LANCET, 355(9211), 2000, pp. 1231-1237
Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma
Authors: Saso, R Kulkarni, S Mitchell, P Treleaven, J Swansbury, GJ Mehta, J Powles, R Ashley, S Kuan, A Powles, T
Citation: R. Saso et al., Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma, BR J CANC, 83(1), 2000, pp. 91-94
Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants
Authors: Kulkarni, S Powles, R Treleaven, J Riley, U Singhal, S Horton, C Sirohi, B Bhagwati, N Meller, S Saso, R Mehta, J
Citation: S. Kulkarni et al., Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants, BLOOD, 95(12), 2000, pp. 3683-3686
Metastatic extramedullary plasmacytoma of the lung
Authors: Wang, J Pandha, HS Treleaven, J Powles, R
Citation: J. Wang et al., Metastatic extramedullary plasmacytoma of the lung, LEUK LYMPH, 35(3-4), 1999, pp. 423-425
The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy
Authors: Mehta, J Powles, R Treleaven, J Swansbury, GJ Kulkarni, S Saso, R Min, T Singhal, S
Citation: J. Mehta et al., The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy, LEUK LYMPH, 34(5-6), 1999, pp. 553-560
Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling
Authors: Singhal, S Powles, R Treleaven, J Kulkarni, S Horton, C Mehta, J
Citation: S. Singhal et al., Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling, LEUK LYMPH, 34(3-4), 1999, pp. 287-294
Risultati: 1-25 | 26-29